Nonrandomized comparison of efficacy and side effects of bicalutamide compared with luteinizing hormone-releasing hormone (LHRH) analogs in combination with radiation therapy in the CHHiP trial
Name:
35017008.pdf
Size:
1.785Mb
Format:
PDF
Description:
Identified with Open Access button
Authors
Tree, A.Griffin, C.
Syndikus, I.
Birtle, A.
Choudhury, Ananya
Graham, J.
Ferguson, C.
Khoo, V.
Malik, Z.
O'Sullivan, J.
Panades, M.
Parker, C.
Rimmer, Y.
Scrase, C.
Staffurth, J.
Dearnaley, D.
Hall, E.
Affiliation
Royal Marsden NHS Foundation Trust, London, United Kingdom; Institute of Cancer Research, London, United KingdomIssue Date
2022
Metadata
Show full item recordAbstract
Purpose: CHHiP is a randomized trial evaluating moderately hypofractionated radiation therapy for treatment of localized prostate cancer. Of all participants, 97% of them had concurrent short-course hormone therapy (HT), either luteinizing hormone-releasing hormone analog (LHRHa) or 150 mg of bicalutamide daily. This exploratory analysis compares efficacy and side effects in a nonrandomized comparison. Methods and materials: In our study, 2700 patients received LHRHa and 403 received bicalutamide. The primary endpoint was biochemical/clinical failure. Groups were compared with Cox regression adjusted for various prognostic factors and stratified by radiation therapy dose. A key secondary endpoint was erectile dysfunction (ED) assessed by clinicians (using scores from Late Effects on Normal Tissues: Subjective/Objective/Management [LENT-SOM] subjective erectile function for vaginal penetration) and patients (single items within the University of California-Los Angeles Prostate Cancer Index [UCLA PCI] and Expanded Prostate Cancer Index Composite [EPIC]-50 questionnaires) at 2 years and compared between HT regimens by χ2 trend test. Results: Bicalutamide patients were significantly younger (median 67 vs 69 years LHRHa). Median follow-up was 9.3 years. There was no difference in biochemical or clinical failure with an adjusted hazard ratio or 0.97 (95% confidence interval, 0.77-1.23; P = .8). At 2 years, grade ≥2 LENT-SOM ED was reported in significantly more LHRHa patients (313 out of 590; 53%) versus bicalutamide (17 out of 68; 25%) (P < .0001). There were no differences in ED seen with UCLA-PCI and EPIC-50 questionnaires. Conclusions: In this nonrandomized comparison, there was no evidence of a difference in efficacy according to type of HT received. Bicalutamide preserved clinician assessed (LENT-SOM) erectile function at 2 years but patient-reported outcomes were similar between groups.Citation
Tree A, Griffin C, Syndikus I, Birtle A, Choudhury A, Graham J, et al. Nonrandomized Comparison of Efficacy and Side Effects of Bicalutamide Compared With Luteinizing Hormone-Releasing Hormone (LHRH) Analogs in Combination With Radiation Therapy in the CHHiP Trial. International journal of radiation oncology, biology, physics. 2022 Jun 1;113(2):305-15. PubMed PMID: 35017008. Pubmed Central PMCID: 9119688.Journal
International Journal of Radiation Oncology Biology PhysicsDOI
10.1016/j.ijrobp.2021.12.160PubMed ID
35017008Additional Links
https://dx.doi.org/10.1016/j.ijrobp.2021.12.160Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.ijrobp.2021.12.160
Scopus Count
Collections
Related articles
- Exploratory analysis on the effect of race on clinical outcome in patients with advanced prostate cancer receiving bicalutamide or flutamide, each in combination with LHRH analogues. The Casodex Combination Study Group.
- Authors: McLeod DG, Schellhammer PF, Vogelzang NJ, Soloway MS, Sharifi R, Block NL, Venner PM, Patterson AL, Sarosdy MF, Kelley RP, Kolvenbag GJ
- Issue date: 1999 Sep 1
- Maximal androgen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Casodex Combination Study Group.
- Authors: Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G
- Issue date: 1996 Jan
- Radiotherapy Plus GnRH Analogue Versus High Dose Bicalutamide: A Case Control Study.
- Authors: Buwenge M, Deodato F, Macchia G, Siepe G, Zhao X, Valicenti RK, Cilla S, Alitto AR, Ntreta M, Bisello S, Mantini G, Valentini V, Morganti AG, Cammelli S
- Issue date: 2019 Nov
- Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
- Authors: Sakai H, Igawa T, Tsurusaki T, Yura M, Kusaba Y, Hayashi M, Iwasaki S, Hakariya H, Hara T, Kanetake H
- Issue date: 2009 Mar
- A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group.
- Authors: Schellhammer P, Sharifi R, Block N, Soloway M, Venner P, Patterson AL, Sarosdy M, Vogelzang N, Jones J, Kolvenbag G
- Issue date: 1995 May